| Literature DB >> 11959397 |
Mikio Shoji1, Etsuro Matsubara, Tetsuro Murakami, Yasuhiro Manabe, Koji Abe, Mitsuyasu Kanai, Masaki Ikeda, Yasushi Tomidokoro, Masami Shizuka, Mitsunori Watanabe, Masakuni Amari, Koji Ishiguro, Takeshi Kawarabayashi, Yasuo Harigaya, Koichi Okamoto, Tsuyosi Nishimura, Yu Nakamura, Masatoshi Takeda, Katsuya Urakami, Yoshiki Adachi, Kenji Nakashima, Hiroyuki Arai, Hidetada Sasaki, Kazutomi Kanemaru, Hiroshi Yamanouchi, Yasuji Yoshida, Kunihiro Ichise, Kuniaki Tanaka, Makoto Hamamoto, Hideki Yamamoto, Takeyuki Matsubayashi, Hiroshi Yoshida, Hiromasa Toji, Shigenobu Nakamura, Shunsaku Hirai.
Abstract
A large scale multicenter study of cerebrospinal fluid (CSF) tau levels was conducted to determine the cut-off value, sensitivity and specificity for clinical usage as a biomarker of Alzheimer's disease (AD). Its use for early and differential diagnosis and the factors that increase CSF tau levels were also examined. CSF samples from a total of 1,031 subjects including 366 patients with AD, 168 patients with non-Alzheimer type dementia (NA), 316 patients with non-dementia neurological diseases (ND) and 181 normal controls (NC) were measured using ELISA for tau. The cut-off value of tau, 375 pg/ml, showed 59.1% sensitivity and 89.5% specificity for diagnosis of AD compared with the other groups. The tau levels were increased from the early to late stages of AD. Elevation of CSF tau in the non-tauopathy and tauopathy dementia groups, chronic and acute damage to the cerebrum, and meningeal disturbance were other factors that required attention for clinical practice. Measurement of CSF tau was useful as a biomarker for early and differential diagnosis of AD.Entities:
Mesh：
Substances：
Year: 2002 PMID： 11959397 DOI： 10.1016/s0197-4580(01)00309-8
Source DB: PubMed Journal: Neurobiol Aging ISSN： 0197-4580 Impact factor: 4.673